Alpha-1 Guardian Program
At CSL Behring, we’re committed to helping patients within the Alpha-1 community live healthier lives. That’s why we’ve partnered with so many organizations to offer you the support, education and guidance you need.
Just call 1-888-415-2167 for answers to a wide range of questions regarding your diagnosis of Alpha-1.
Breathe easier. We’re here for you.
What is the Alpha-1 Guardian Program? The Alpha-1 Guardian Program is a personal health management program that offers support, guidance and education for patients with Alpha-1.
Who is eligible for the Alpha-1 Guardian Program? Patients currently using Zemaira® and patients who start therapy with Zemaira® in the future are eligible to participate in the program.
What services does the Alpha-1 Guardian Program provide? The Alpha-1 Guardian Program offers individualized case management, including:
Detailed insurance benefits investigation
- Acquisition of insurance coverage and alternative coverage options
- Prior authorization assistance
Financial assistance
- Insurance funding for those in need, with help from the Caring Voice Coalition, a not-for-profit charitable agency
Patient assistance
- Enrollment in a Patient Assistance Program to help you get medication
Assurance Program
- Augmentation therapy up to a maximum of 12 months without charge in the event of a lapse in insurance coverage for patients using CSL Behring products
Alpha-to-Alpha—supportive, personal mentoring
- Education and assistance with augmentation therapy
- Answers to infusion and supply questions
- Self-management strategies
- Information on available resources for managing daily issues
One number…many resources. Just call 1-888-415-2167.
Important Safety Information
Alpha1-Proteinase Inhibitor (Human), Zemaira® is indicated for chronic augmentation and maintenance therapy for adults with alpha1-proteinase inhibitor (A1-PI) deficiency and emphysema. Clinical data demonstrating the long-term effects of chronic augmentation therapy with Zemaira® are not available.
Zemaira® may not be appropriate for the following adult individuals as they may experience severe reactions, including anaphylaxis: individuals with a known hypersensitivity and/or history of anaphylaxis or severe systemic reaction to A1-PI products or their components, and individuals with selective IgA deficiencies who have known antibodies against IgA.
In clinical studies, the following treatment-related adverse reactions were reported in 1% of subjects: asthenia (fatigue), injection-site pain, dizziness, headache, paresthesia (tingling), and pruritus (itching).
Zemaira® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.
Please see full prescribing information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.